Small Business Resources, Business Advice and Forms from AllBusiness.com

Holding out hope: a drug trial in Orlando looks promising.(Executive Lifestyles: Health: Breast...

By Sears, Diane
Publication: Florida Trend
Date: Sunday, October 1 2006

A not-yet-released drug that shows promise in treating patients with aggressive HER2-positive breast cancer is now available in clinical trials in Orlando and a handful of other sites nationwide.

The M.D. Anderson Cancer Center on the Orlando Regional Healthcare campus has been receiving calls from women as far away as the Czech Republic, Israel and Canada to participate in an expanded access trial for lapatinib, marketed under the name Tykerb by GlaxoSmithKline. This type of trial is the final step before a drug is approved by the U.S. Food and Drug Administration to b

In addition, make sure to read these premium articles also available with your free trial:

  • Genentech, Inc.premium_logo
    • 1 DNA Way South San Francisco, CA 94080-4990 650-225-1000 www.gene.com Genentech BioOncology continued to make significant progress in 2001. Combined product sales of Herceptin and ......
  • New options: increased funding is fueling new developments for...premium_logo
    • Breast cancer cases nationwide have tripled in the past 30 years, and the disease is now stoking patients in their 20s and 30s instead of ......
  • ONCOGENEX BEGINS FIRST OF 4 PHASE 2 CLINICAL 0GX-011 TRIALS.premium_logo
    • OncoGenex Technologies Inc., Vancouver, has initiated a Phase 2 clinical trial of OGX-011 in newly diagnosed, previously untreated patients with clinically localized, high-risk prostate carcinoma....
  • FDA APPROVES LORUS/NCI GTI-2040 PHASE II CLINICAL TRIAL.premium_logo
    • Lorus Therapeutics Inc., Toronto, Canada, has announced that the U.S. Food and Drug Administration has approved the U.S. National Cancer Institute's (NCI) Investigational New Drug ......
  • SLOAN CANCER VACCINE PHASE III STUDY BEGINS.premium_logo
    • Merck KGaA, Darmstadt, Germany, has announced that the first patient has been enrolled in its global Phase III clinical study, START (Stimulating Targeted Antigenic Responses ......
  • Genentech, Inc.premium_logo
    • 25 YEARS IN BUSINESS FOR LIFE Xanelim [TM] (Efalizumab) is an anti-CD11 a humanized monoclonal antibody designed to block certain immune cells as a potential ......
  • PIERRE FABRE LICENSES PHARMAGENESIS ANTI-CANCER HERBAL DRUG.premium_logo
    • Pharmagenesis, Inc., a research and development company based in Palo Alto developing anti-cancer therapies, has signed an agreement with Pierre Fabre Medicament (PFM), a European ......
  • IGENEON AND IMMUNICON FORM DEVELOPMENT ALLIANCE.premium_logo
    • Immunicon Corporation and igeneon have formed a clinical collaboration aimed at the registration of igeneon's cancer immunotherapies and to expand the indications for use of ......
  • Genentech, Inc.premium_logo
    • Genentech, Inc. is a leading biotechnology company focusing on the discovery, development, manufacture and marketing of pharmaceuticals that address significant unmet medical needs. * The ......
  • Genesis Bioventures.premium_logo
    • Genesis Bioventures ("GBI"), officially known as BioLabs, Inc., is a New York biomedical development corporation focused on facilitating the development and marketing of novel cancer ......
T T T
art_print Printart_email Email 16x16-digg-guy  Digg It delicious-small  del.icio.us

Related Resources

Free AllBusiness Articles

  • Scientific misconduct revealed in high-dose chemotherapy trials.
    • Last year Dr. Werner Bezwoda of the University of Witwatersrand in Johannesburg admitted that he falsified data in a study that showed bone-marrow transplantation and high-dose chemotherapy could prolong the lives of some women with breast cancer that spread to their lymph nodes. His admission and retraction of results came ......
  • Preliminary data shows HDC+BMT combo therapy doesn't affect breast cancer survival rate; results questioned.
    • The combination of high-dose chemotherapy plus bone marrow transplantation (HDC+BMT) in women with advanced breast cancer does not confer a survival advantage compared with conventional chemotherapy and radiation, according the American Society of Clinical Oncology (ASCO). Only 1 in 5 studies conducted over the past 10 years in the United ......
  • Galenica acquisition finalized.
    • Australian Cancer Technology (Sydney, Australia) chairman Roger Aston and managing director Paul Hopper announced from New York that due diligence on the proposed US$5 million Galenica Pharmaceuticals (Birmingham, AL) acquisition was completed satisfactorily and final documentation signed today. The acquisition is now subject only to the approval of AustCancer shareholders ......
  • HDC+BMT treatment option for breast cancer patients should continue to be evaluated, NCI researchers say.
    • High-dose chemotherapy plus bone marrow transplantation (HDC+BMT) may still prove to be a viable option for some breast cancer patients and should continue to be evaluated in clinical trials, according to leading researchers at the National Cancer Institute (NCI) and elsewhere. In an open letter to members of the American ......
  • Introgen obtains patent for p53 targeted chemotherapy.
    • Introgen Therapeutics, Inc. (Austin, TX) and The University of Texas M. D. Anderson Cancer Center announced that the United States Patent and Trademark Office has issued to The Board of Regents of The University of Texas System United States Patent 6,410,029 entitled "2-Methoxyestradiol-induced apoptosis in cancer cells." 2-methoxyestradiol is a ......
  • Niche market.
    • Abraxane, the first proprietary drug by American Pharmaceutical Partners Inc., seems likely to capture the market for treating breast cancer patients who have failed prior rounds of chemotherapy. The Schaumburg, Ill., genetic drug manufacturer, controlled by Los Angeles-based Dr. Patrick Soon-Shiong, released clinical trial data recently showing that the drug ......
  • Pharmaceutical companies focus on women
    • Before the year's end, Whitehouse Station-based Merck & Co. expects to submit a Biologics License Application with the FDA for a cervical cancer vaccine Gardasil. In a 12,000-patient Phase III trial, Gardasil - quadrivalent human papillomavirus types 6, 11, 16, 18, recombinant vaccine - prevented 100 percent of high-grade cervical ......

Blogs

  • October is National Breast Cancer Awareness Month (NBCAM)
    • In conjunction with National Breast Cancer Month (NBCAM), the Centers for Medicare & Medicaid Services (CMS) would like to invite you to join with us in helping to promote increased awareness of the importance of early detection of breast cancer, and ensure that all eligible women with Medicare know that ......
  • Patient expectations and mammograms
    • A study out today suggests that public education campaigns can work too well: women overestimate their risk of breast cancer and overestimate the ability of mammograms to detect tumors. It's a good thing that women are aware and will go for mammograms. It's a bad thing when women gain a ......
  • Carnivale of Customer Service--Best Practice III
    • This is the last post in this edition of the Carnivale of Customer Service. I don't know about you, but I'm "carnivaled out." There have been something like 19 posts, including this one. I'm whupped! But wait! Our last post is a little different. Nettie Hartsock, also an Allbusiness.com blogger, ......
  • What is obvious, Alex
    • A study from the Mayo Clinic demonstrates an improved rate of routine mammograms when a web-based recall tracking system is used. Proactice recalls of patients for routine preventive services is good medicine, puts the physician as the central health advisor for patients, AND earns fees for the practice.
  • All Bloggers
Related Topics
Tools

Sponsored Links

Site Map | Contact Us | FAQs | About Us | Media Kit | Reprints | RSS Directory | Sign Up for Free Newsletters | Disclosure Policy

Copyright © 1999 - 2008 AllBusiness.com, Inc. All rights reserved.
No part of this content or the data or information included therein may be reproduced,
republished or redistributed without the prior written consent of AllBusiness.com.
Use of this site is governed by our Copyright and Intellectual Property Policy, Terms of Use Agreement and Privacy Policy.

Get In-Depth Company Information from Hoover's | Buy a D&B Credit Report | What is in Your Company's D&B Credit Report? | Article Archives
Online Business Database | Online Business Information | Email Marketing Lists | Sales and Marketing Solutions | Business Mailing Lists
Information and opinions on AllBusiness.com solely represent the thoughts and opinions of the authors and are not endorsed by, or reflect the beliefs of,
AllBusiness.com, its parent company D&B, and its affiliates.